spacer
home > directory > Alfasigma
PHARMACEUTICAL INDUSTRY DIRECTORY

Alfasigma

Alfasigma
 Alfasigma is one of the leading Italian pharmaceutical company, focused on prescription drugs, self-medication and nutraceutical products. Established in 2015, after the merge of Alfa Wassermann and Sigma-Tau, today it is present with branches and distributors in around 90 countries worldwide.

In 2018 Alfasigma exceeded 1 billion Euro of turnover, half of which generated by foreign markets.

Alfasigma’s strategy is based on three guidelines which, over the years, have assured the group constant and balanced growth: Research, Technology and Internationalization.

Implementing research and technology to constantly improve its products, opening up new frontiers, extending to new markets.

During the years it has invested heavily in plant and human resources and currently has over 2,800 employees and five manufacturing plants covering almost 500,000 square metres.

As a result of the last investments, two new sterile departments for sterile powder and pre-filled syringes will become fully operational in 2020. The first, will be dedicated to the production of vials filled with sterile powders and liquids.

Attention to quality is a high priority for Alfasigma and the standards it applies comply with FDA, ANVISA, GCC, PMDA and EUGMP requirements.
email contractmanufacturing@alfasigma.com
web manufacturing.alfasigma.com
email Alfasigma S.p.A. Alanno (PE), Via E.Fermi, 1 Pomezia (RM), Via Pontina, km 30,400
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

Clinical Trial Supply New England

24-25 March 2020, Boston, US

Following on from another successful conference Arena International will be returning with full force to Waltham in March to celebrate another edition of the Clinical Trial Supply show. 2020 will gather the key stakeholders in the clinical trials community, including the FDA, US Customs and Border Protection, Biogen, Sanofi, and Blueprint Medicines Corporation. With interactive session formats, fresh content and networking, the event will provide attendees with an unparalleled opportunity for collaboration between players across the whole industry.
More info >>

 
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement